Orthofix Medical (NASDAQ:OFIX) CEO Massimo Calafiore Sells 9,600 Shares

Orthofix Medical Inc. (NASDAQ:OFIX) CEO Massimo Calafiore sold 9,600 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $15.82, for a total value of $151,872.00. Following the completion of the sale, the chief executive officer owned 227,034 shares in the company, valued at $3,591,677.88. The trade was a 4.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Massimo Calafiore also recently made the following trade(s):

• On Monday, January 12th, Massimo Calafiore sold 9,797 shares of Orthofix Medical stock. The stock was sold at an average price of $15.21, for a total transaction of $149,012.37.

Orthofix Medical Stock Performance

Shares of NASDAQ OFIX traded down $0.44 during midday trading on Tuesday, hitting $14.81. 187,589 shares of the company’s stock traded hands, compared to its average volume of 227,586. The stock has a market capitalization of $586.48 million, a price-to-earnings ratio of -4.89 and a beta of 0.79. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.38 and a current ratio of 2.47. The firm has a fifty day moving average of $15.39 and a 200 day moving average of $14.23. Orthofix Medical Inc. has a 1 year low of $10.24 and a 1 year high of $20.48.

Analysts Set New Price Targets

OFIX has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a research note on Wednesday, October 8th. Barrington Research upped their price objective on Orthofix Medical from $17.00 to $18.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Finally, Stifel Nicolaus began coverage on Orthofix Medical in a research report on Tuesday, October 28th. They set a “buy” rating and a $22.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Orthofix Medical has a consensus rating of “Moderate Buy” and a consensus price target of $21.50.

Institutional Investors Weigh In On Orthofix Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OFIX. Paradigm Capital Management Inc. NY raised its holdings in Orthofix Medical by 34.6% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock valued at $37,248,000 after buying an additional 858,900 shares during the period. Millennium Management LLC increased its position in shares of Orthofix Medical by 86.6% during the third quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company’s stock valued at $21,605,000 after acquiring an additional 684,850 shares during the last quarter. Bank of America Corp DE increased its position in shares of Orthofix Medical by 659.5% during the second quarter. Bank of America Corp DE now owns 687,410 shares of the medical device company’s stock valued at $7,665,000 after acquiring an additional 596,907 shares during the last quarter. Engine Capital Management LP raised its stake in shares of Orthofix Medical by 13.6% in the 2nd quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company’s stock valued at $47,406,000 after acquiring an additional 510,281 shares during the period. Finally, AYAL Capital Advisors Ltd lifted its holdings in shares of Orthofix Medical by 74.7% in the 2nd quarter. AYAL Capital Advisors Ltd now owns 943,203 shares of the medical device company’s stock worth $10,517,000 after acquiring an additional 403,433 shares during the last quarter. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.